Longeveron Inc. (NASDAQ:LGVN), a biopharmaceutical company specializing in regenerative medicine with a market capitalization of $23.81 million, announced the immediate resignation of Mr. Neil Hare ...

Company has disclosed the compensation details for its CEO and President, Charles W. Scharf, who will receive $31.2 million for his performance in 2024. The announcement was made following approval by ...